Background
==========

In recent decades, it has been standard practice when treating non-small cell lung carcinoma (NSCLC) to deliver 40 to 50 Gy to the uninvolved regional lymph nodes. Known as elective nodal irradiation (ENI), this therapy is targeted to ipsilateral and contralateral hilar/mediastinal nodes and occasionally to supraclavicular areas, with an additional 20 Gy delivered to the primary gross tumor through reduced fields \[[@B1]\].

In the era of 2-dimensional radiotherapy before the advent of positron emission tomography (PET) scanning for staging and before the use of adjunctive chemotherapy (CHT), Radiation Therapy Oncology Group (RTOG) studies had shown a potential survival benefit from ENI in stage III NSCLC \[[@B1]\]. The staging of regional lymph node involvement has been greatly enhanced with the help of PET. The addition of PET to clinical mediastinal staging with CT has improved sensitivity and specificity compared with CT alone. More accurate clinical staging with PET allows the radiation oncologist to include involved hilar and mediastinal nodes that were not visualized on the CT scan and thereby reduce the probability of elective nodal failure (ENF) \[[@B2]\]. Therefore, the concept of ENI has been challenged with recent data showing very low rates of elective nodal failure (ENF) using only involved-field radiation therapy (IFRT) without ENI in the era of computed tomography (CT)-based 3-dimensional conformal radiotherapy (3D-CRT) \[[@B3]\].

However, these results have been met with caution, and a recent survey reported that only 26% of the members of the American Society of Therapeutic Radiation Oncology treat NSCLC without ENI \[[@B4]\]. The most recent analysis of the pertinent literature conducted by the International Atomic Energy Agency concluded that the indication for ENI in such cases is uncertain \[[@B5]\]. It appears that more studies are needed to address this issue.

In our large single-institution study, we report the clinical outcome and pattern of failure of 3D-CRT without ENI in treating NSCLC after staging with PET scanning.

Methods
=======

Patient selection and cancer staging
------------------------------------

We retrospectively reviewed the clinical records of all consecutive patients who began their external beam radiation therapy for NSCLC during 2002 at The University of Texas M. D. Anderson Cancer Center. Patients were included for analysis if they were diagnosed with histologically or cytologically proven NSCLC not previously treated, received \> 50 Gy definitive radiation to the primary tumor, had tumors stage I to IIIB, had pre- and post-treatment CT images available for review, and had complete radiation treatment records. Patients who had multiple lobes in the lung treated simultaneously were included based on the assumption that their tumors consisted of synchronous primary tumors. Disease was staged using chest CT and brain magnetic resonance imaging (MRI) in all patients. PET was also used for staging 75% of patients. Several patients were treated on clinical protocols involving induction or concurrent CHT. The majority of patients with locally advanced disease received concurrent platinum-based CHT along with their radiation therapy. This study was conducted with the approval of the Institutional Review Board (study RCR05-0263).

Radiation treatment
-------------------

Patients were treated using 3D conformal techniques planned using CT-based Pinnacle planning software (Philips Medical System, Andover, MA). Patients were treated in the supine position with their arms raised above their heads and were immobilized using a custom-made Vac-Lok cradle (Medtec, Orange City, IA). Gross tumor volume (GTV) was delineated based on the assessment of abnormalities in the CT images. We focused on the lung window to assess lung parenchymal disease and on the mediastinal window to assess lymph node and mediastinal involvement. When PET or PET/CT images were available, metabolically active lymph nodes were included in the GTV even if they appeared grossly normal on CT. Likewise, involved nodal regions diagnosed by histologic evaluation of biopsies taken during mediastinoscopy were also included in the GTV. Suspicious lymph nodes (\> 1 cm in the shortest dimension) were included as well.

Clinical target volume was defined as the GTV plus an 8-mm margin to account for microscopic disease. First-echelon lymph nodes were included in the clinical target volume in some cases, if they were visible and adjacent to the gross disease and if coverage of these nodes did not elevate normal tissue toxicity significantly, as decided on an individual basis by the radiation oncologist. For the right mid lobe or right lower lobe, left lingular, or left lower lobe lesion, if a mediastinal lymph node was involved, the ipsilateral hilar and subcarinal lymph nodes were treated to 45--50 Gy. For a left upper lobe lesion, the aorto-pulmonary window lymph node were treated to 45--50 Gy if there was mediastinal lymph node involvement. Otherwise uninvolved elective nodal regions that might previously have been considered eligible for prophylactic treatment were excluded. Tumor motion was evaluated based on location, clinical judgment, and x-ray fluoroscopy. Another 10- to 15-mm margin was added to the planning target volume to take tumor motion and set-up uncertainty into consideration. Correction was made for tissue inhomogeneity in all treatment plans. Treatment was delivered using 6-MV or higher X-rays from a linear accelerator and typically consisted of three or four treatment fields, depending on the location of the tumor.

Clinical endpoints
------------------

Clinical endpoints examined included overall survival, disease-free survival, locoregional recurrence, and distant metastasis (DM). At follow-up, patients were given chest CT scans every 3 months for 2 years and then every 6 months for 3 years. PET scans were commonly used to evaluate treatment response 3 to 6 months after the completion of radiotherapy and/or CHT. Clinical responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) based on both PET and CT images \[[@B6]\]. Local tumor recurrence was defined as progressive abnormal CT images corresponding to avid lesions on PET images obtained during routine patient follow-up. When a failure was noted in the clinical record, all imaging prior to that time was carefully reviewed and the date of failure coded based on the date the recurrence was first visible radiographically. Locoregional recurrences were classified as IFF if the majority of the recurrent tumor volume or an obvious origin of tumor recurrence was located within the radiation treatment field PTV. Locoregional failures were coded even if they occurred subsequent to DM. ENF was defined as any recurrence outside the treatment volume but located within bilateral hila, mediastinal lymph node regions, and bilateral supraclavicular areas (for upper lobe lesions). Isolated ENF was considered only in the absence of IFF and DM.

In cases of ENF, the site of recurrence was superimposed on the original treatment planning CT images and a recurrent tumor volume approximated. The mean dose received by this volume during the original treatment was determined using the treatment planning software to estimate dose to the nodal region that experienced recurrence. IFFs were presumed to have received the fully prescribed treatment dose.

Statistics
----------

Durations of survival and time-to-failure were determined from the date of pathologic diagnosis, and survival probabilities were determined by the Kaplan-Meier method using JMP 6.0.3 for Macintosh (SAS Institute, Cary, NC). Patients for whom the cause of death was unknown were coded as dead of disease. Timing of recurrence was scored at the time of the first image (PET and/or CT) that showed abnormalities.

Results
=======

Patient population and treatment
--------------------------------

Table [1](#T1){ref-type="table"} shows the characteristics of 115 consecutive patients with stage I to III NSCLC treated with 3D-CRT in 2002 at our institution (Table [1](#T1){ref-type="table"}). The median follow-up time was 18 months (range, 3 to 49 months). The majority of patients had good performance status, with 89% categorized as either ECOG 0 or 1. Eighty-eight (77%) patients presented with locally advanced (stage III) disease and 80 (91%) patients received concurrent CHT as part of their treatment. Forty-four (38%) patients participated in prospective clinical trials. Radiation doses ranged from 58 to 69.6 Gy, with the majority of patients treated with either 63 Gy in 35 or 60 Gy in 30 daily fractions with concurrent CHT for stage III disease, 66 Gy in 33 daily fractions without CHT for stage 1 disease, or 69.6 Gy given as 1.2 Gy/fraction twice a day with concurrent CHT for stage III disease in the superior sulcus location.

###### 

Patient characteristics (N = 115)

  ----------------------------------------- ---------------
  Median age, years (range)                 65 (35 -- 92)
  Median follow-up, months (range)          18 (3 -- 49)
  Sex (%)                                   
   male                                     58 (50)
   female                                   57 (50)
  ECOG performance status (%)               
   0                                        31 (27)
   1                                        71 (62)
   2                                        8 (7)
   3                                        1 (1)
   Unknown                                  4 (3)
  Weight loss before treatment (%)          
   ≥ 10%                                    24 (21)
   \< 10%                                   91 (79)
  AJCC stage grouping (%)                   
   IA/IB                                    22 (19)
   IIA/IIB                                  5 (4)
   IIIA                                     34 (30)
   IIIB                                     54 (47)
  Comorbidities (%)                         
   COPD                                     30 (26)
   Cardiovascular disease                   59 (52)
   Smoker                                   100 (87)
  Pathologic classification (%)             
   Adenocarcinoma                           43 (37)
   Squamous cell carcinoma                  39 (34)
   Large cell carcinoma                     3 (3)
   Mixed                                    2 (2)
   Non-small cell not otherwise specified   28 (24)
  Grade (%)                                 
   Well-differentiated                      7 (6)
   Moderately differentiated                12 (10)
   Poorly differentiated                    55 (48)
   No grade indicated                       41 (36)
  Location (%)                              
   Right                                    63 (54)
   Left                                     49 (43)
   Mediastinal nodal disease only           3 (3)
  Staging workup (%)                        
   PET scan performed                       86 (75)
   Mediastinoscopy performed                16 (14)
  Chemotherapy (%)                          
   Induction                                55 (47)
   Concurrent                               
    Taxane/platinum based                   62 (54)
    Other                                   18 (16)
  Treated on clinical protocol (%)          44 (38)
  Radiation treatment (%)                   
   Mean dose                                64 Gy
   \> 66 Gy                                 8 (7)
   \> 63 -- 66 Gy                           29 (25)
   60 -- 63 Gy                              75 (65)
   \< 60 Gy                                 3 (3)
   Mean treatment duration (days)           45
  ----------------------------------------- ---------------

A total of 115 patients (58 men and 57 women) were analyzed in this study, including 27 stage I/II and 88 stage IIIA/B cases. The median age at diagnosis was 65 years (range, 35 to 92). As noted, 75% of patients underwent PET for staging. Also, 70% of all patients and 85% of patients with stage IIIA/B disease received concurrent, platinum-based CHT.

Clinical outcome and pattern of failure
---------------------------------------

The median follow-up time was 18 months (3 to 44 months) among all patients and 27 months (6 to 44 months) among survivors. The median overall survival duration and 2-year actuarial overall survival and disease-free survival percentages were 19 months, 38%, and 28%, respectively (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![**Pattern of failure**. A. Probability of any disease recurrence by Kaplan-Meier method. B. Pattern of Failure. Distant metastasis (DM) remains the most common site of disease failure, followed by IFF and any ENF (p \< 0.0001, log-rank test). Five of 115 patients developed ENF and only 2 of 5 ENFs were isolated ENFs.](1748-717X-4-5-1){#F1}

###### 

Patient outcomes (N = 115).

  ------------------------------------ -------------
  Overall survival\*                   
   Median (months)                     19
   1-yr (%)                            72
   2-yr (%)                            38
  Distant metastasis-free survival\*   
   Median (months)                     35
   1-yr (%)                            90
   2-yr (%)                            60
  Local control\*                      
   Median (months)                     not reached
   1-yr (%)                            83
   2-yr (%)                            60
  Disease-free survival\*              
   Median (months)                     14
   1-yr (%)                            63
   2-yr (%)                            28
  ------------------------------------ -------------

\* Kaplan-Meier method.

The leading cause of death among the patients was DM and the overall rate of DM was 36%. Of the 31 patients with local regional failure, 26 (22% of patients overall) had IFF. The other 5 patients (4.3% of all patients) developed ENF (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Two of the 5 patients (1.7% of the overall group) developed isolated ENF as the first site of failure, whereas the other 3 patients developed in-field recurrence followed by out-of-field recurrence (any ENF). All of the elective nodal failures occurred in regions that did not receive a therapeutic dose of incidental radiation (\> 45 Gy, Table [4](#T4){ref-type="table"}). The Representative cases of ENF were shown in Figure [2](#F2){ref-type="fig"}. The locations of recurrence were mixed and not clearly predictable on the basis of the location of the primary tumor. For all 88 patients with stage IIIA/B, the frequency of IFF, ENF, isolated ENF, and DM were 23 (26%), 3 (3.4%), 1 (1.1%), and 36 (40.9%), respectively. Of the 27 patients with early-stage node-negative disease (stage IA/IB), 3 had IFF (11.1%), 1 had ENF (3.7%), 0 had isolated ENF (0%), and 5 had DM (18.5%). All 5 patients with ENF underwent PET for staging, and 1 of these patients was alive at the last follow-up (at 44 months).

![**Representative coronal reconstructions from planning CT images demonstrating locations of ENF**. The green contour represents ENF. The approximate location of the recurrences based on diagnostic CT imaging performed at the time of the recurrence is indicated (shaded area). A. Patient \#4, isolated ENF. B. Patient \#5, not isolated ENF. Refer to Table [4](#T4){ref-type="table"} for details regarding the sites of primary disease and recurrences.](1748-717X-4-5-2){#F2}

###### 

Disease recurrence pattern.

                                                            N (%)
  --------------------------------------------------------- -----------
  First site of failure (56 failures among 115 patients)    
   Isolated Elective nodal failure                          2 (1.7)
   In-field failure                                         18 (15.7)
   Distant metastasis                                       36 (31.3)
  Any Elective nodal failures (isolated and non-isolated)   5 (4.3)
   Stage I/II                                               2
   Stage III                                                3

###### 

Patient characteristics for patients with any failures in elective nodal regions

  Patient with ENF   T-Stage   N-Stage   Pathologic diagnosis   Primary tumor location                                     Dose (Gy)   Chemotherapay                                     Site of failure                                           Dose to failure site (Gy)
  ------------------ --------- --------- ---------------------- ---------------------------------------------------------- ----------- ------------------------------------------------- --------------------------------------------------------- ---------------------------
  1                  2         1         Squamous               Left hilum                                                 60          None                                              Right supraclavicular\*                                   \< 1.0
  2                  4         3         Adenocarcinoma         Left lower lobe                                            63          Concurrent carboplatin/paclitaxel                 Ipsilateral mediastinum                                   22.5
  3                  2/1       0/0       Adenocarcinoma         Left lower lobe/right upper lobe†                          66          None                                              Left hilum, Left supraclavicular, Right supraclavicular   23.3, 24.4, 44.3
  4                  2         3         Adenocarcinoma         Right upper lobe                                           60          Induction and concurrent carboplatin/paclitaxel   Right supraclavicular\*                                   10.7
  5                  2         3         Squamous               Right upper lobe, contralateral mediastinum, right hilum   63          Concurrent carboplatin/paclitaxel                 Left hilum                                                30.4

\* Site of first failure in isolated elective nodal region.

† Synchronous primary tumor

Discussion
==========

Using PET for staging and treatment design, we found that definitive 3-D radiotherapy without ENI was associated with less than 2% isolated ENF in our study. IFRT alone appears adequate for inoperable NSCLC. The main rationale for foregoing ENI is that gross disease is not being controlled according to the high local recurrence rates (22%) within the previously irradiated tumor volume and the high rates of DM (36%). If gross disease cannot be controlled, then enlarging the irradiated volumes to include areas that might harbor microscopic disease seems unnecessary. Three major factors have changed since RTOG 73-01 established standard irradiation doses and volumes (including ENI): the advent of CT-based 3D-CRT, the use of chemotherapy, and better staging and target delineation using PET.

Emerging clinical data show that omitting prophylactic lymph node irradiation does not reduce the local control rate for patients receiving definitive radiotherapy, with isolated ENF rates of 0% to 8% \[[@B5]\]. Rosenzweig and colleagues recently published results for a series of 524 patients treated definitively with 3D-CRT targeted to involved-field volumes without ENI \[[@B7]\]. Only 6.1% of patients suffered isolated ENF, while 49% developed IFF. Belderbos et al also reported a 3% isolated ENF rate in patients with PET-staged NSCLC receiving dose-escalated radiotherapy without ENI \[[@B8]\]. Senan and colleagues reported no ENF in patients with stage III disease treated with 70 Gy of radiation without ENI \[[@B9]\]. A recently published randomized trial also supported the benefit of IFRT, with improved overall survival using dose-escalation in the IFRT arm but not in ENI arm \[[@B10]\]. The multicenter study RTOG 9311 also showed that only 6.7% patients developed isolated ENF in NSCLC treated with dose-escalated 3D-CRT without ENI \[[@B11]\].

The explanation for these lower-than-expected ENF rates could be twofold. First, incidental doses to the ipsilateral hilum, paratracheal, and subcarinal nodes approach 40 to 50 Gy when these regions are not intentionally irradiated \[[@B12]\]. Second, lung cancer patients have multiple competing causes of mortality, including cancer and underlying comorbid illnesses. Patients may die of local failure, distant failure, or intercurrent illness without detection of ENF. Therefore, considering the high percentages of IFF/DM and the short duration of overall survival using the current dose (60 to 70 Gy) and technique (3D-CRT) of therapy, the very low rate of isolated ENF justifies the use of IFRT alone in NSCLC.

PET scanning used for staging in our study may explain our very low rate (1.7%) of isolated ENF compared with other studies that did not use PET scans \[[@B5]\]. In addition, our recent published data has shown that tumor size and PET standardized uptake value (SUV) predicted the chance of IFF accurately \[[@B13]\]. In NSCLC, the chance of IFF was 100% when the SUV for lymph node(s) was above 13.8 compared with 15% when the SUV was less than or equal to 13.8 \[[@B13]\]. We found the SUV of the primary tumor to have the same predictive value. Thus, in patients with NSCLC, it is important to deliver adequate doses of radiation to the involved nodal or mediastinal areas, particularly those areas with high SUVs. Adjusting the dose to deliver higher levels of radiation to high-SUV areas seems to be indicated.

Efforts to improve local control in patients treated with radiation therapy for NSCLC have led to the development of dose escalation strategies and concurrent chemoradiotherapy. However, significant toxicities are associated with dose escalation and concurrent CHT and, therefore, ENI needs to be minimized \[[@B14]\]. However, evolution of the increasingly conformal treatment approaches such as IMRT and proton therapy may reduce incidental doses to the elective nodal region \[[@B15]\]. The data from our undergoing clinical trials using IMRT or proton therapy in stage III NSCLC will provide valuable information about the impact of incidental doses on ENF. In addition, as we improve our clinical outcomes (with lower rates of IFF and longer survival) with dose escalated radiotherapy and concurrent CHT, we should re-analyze the ENF data. As patients survive longer and IFF is reduced, the microscopic disease in the elective nodal region may become a greater issue.

In our study, the low rates of isolated ENF were not a consequence of unusually high rates of IFF, which can reduce the observed rate of isolated ENF. The 1- and 2-year local control rates of 83% and 60% were comparable to those previously reported \[[@B11]\]. The pattern of ENF does not suggest any needed modifications to the treatment fields. The ENFs occurred in patients of diverse stages, treatment approaches, and tumor locations. Only 2 of the 5 patients with ENF developed recurrences in next order draining lymphatics. Furthermore, of the 5 ENFs, 3 occurred after IFF and may represent the spread of in-field recurrences rather than true ENF.

In this study, the target volume was generally restricted to involved regions, with some of the first-echelon nodes treated if they were visible and adjacent to gross disease and if coverage of these nodes would not change normal tissue toxicity significantly, as decided on an individual basis by the radiation oncologist. This approach was supported by the observation that the highest rates of micrometastatic disease in mediastinal lymph nodes occurred nearest to the tumor, mainly in peribronchial and hilar locations \[[@B16]\]. Many factors are currently considered in the decision to include first-echelon nodes, such as imaging characteristics of the lymph nodes, proximity to the primary tumor, and the ability to meet dose constraints. Recently, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has become widely used to stage mediastinal lymph nodes. Dr. Herth et al \[[@B17]\] reported that EBUS-TBNA detected lymph node involvement in 9/97 patients with clinical stage I NSCLC with a normal CT image and negative PET of lymph node areas. EBUS-TBNA may be considered to verify the lymph node involvement for suspicious lymph nodes in GTV delineation. This procedure may further improve the accuracy of lymph node staging and target delineation. It should be noted, however, that the sensitivity of EBUS-TBNA is about 90% and common lymph node stations sampled are level 2, 4, 7, 10 and 11 but not level 5, 6, 8 and 9.

Conclusion
==========

In the current era of PET-guided radiation treatment planning and 3D-CRT, restricting the target volume to involved nodal regions results in minimal (\< 2%) isolated ENF. ENI does not appear to be indicated for unresectable NSCLC. Future strategies should continue to be directed at improving in-field control and preventing distant metastatic disease.
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